Community curated by people like you

Tau protein stories

May 14, 2026

Biogen Advances Tau-Targeting Alzheimer's Drug to Phase 3 Despite Mixed Phase 2 Results

Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies following a Phase 2 trial that showed mixed results.

May 14, 2026·1 source

00

Top claims

▪The Phase 2 study of diranersen failed to achieve its primary efficacy goal, which was a dose response.
▪Biogen investigated three escalating dosing regimens in the Phase 2 study of diranersen.
▪Diranersen targets the protein tau, which is toxic to neurons and is believed to play a role in cognitive decline in Alzheimer's patients.

Topics

Alzheimer’s & dementia Alzheimer's disease Clinical trials Drug development

Featured Stories

OpenAI pauses development of Astra AI model over critical cybersecurity capability concerns

OpenAI pauses development of Astra AI model over critical cybersecurity capability concerns

Aug 7, 2026·2 sources